Each stack targets a specific combination of goals
Aziz Pirani, MD and Dr
There's a growing contingent choosing a third option - stacking multiple compounds designed not just to maintain what they had at 25, but to optimize for the decades ahead
Once commercially available (expected late 2026-2027), brand-name retatrutide pricing will likely mirror or exceed tirzepatide pricing, given Eli Lilly manufactures both compounds and the market dynamics of premium obesity medications
Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2) Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions 1,5 Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis Medication interactions may occur with those on insulin, oral diabetes medications, oral contraceptives, and blood thinners
10.1200/JCO.2010.28.0982 165 RugoH
